CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年6月8日～2025年6月14日の間に収集した論文情報を追加しました。

  1. Comprehensive Post-marketing safety analysis of Tildrakizumab: insights from the FDA adverse event Reporting system.

  チルドラキズマブの安全性プロファイルに関する研究

  対象DB：FAERS

  2. Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

  薬剤と手根管症候群発生の関連性に関する研究

  対象DB：FAERS

  3. Cardiovascular Safety Profile of BRAF and MEK Inhibitors in Melanoma: FAERS Data Through a Retrospective Disproportionality Analysis (2014-2023).

  BRAF/MEKi療法における心血管有害事象の調査とその影響

  対象DB：FAERS

  4. Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database.

  ICIの心臓関連副作用に対する性別・年齢差の影響分析

  対象DB：FAERS

  5. A real-world population-based study on the association between cataracts and antipsychotics.

  抗精神病薬と白内障発生リスクのRWD分析

  対象DB：FAERS

  6. Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, plecanatide, and Tenapanor: analysis of the FDA adverse event reporting system (FAERS) database.

  IBS-C治療薬の有害事象分析とその臨床的影響

  対象DB：FAERS

  7. Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer.

  乳がん治療用ADC薬の安全性プロファイルと監視の必要性

  対象DB：FAERS

  8. Pharmacovigilance Analysis of Lifitegrast-Associated Adverse Events Using the FDA Adverse Event Reporting System (FAERS) Database.

  リフィテグラストのRWDによる安全性プロファイル分析

  対象DB：FAERS

  9. Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR databases.

  H1RAsと広範認知症リスクの関連性分析

  対象DB：CVAR,FAERS,JADER

  10. Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system.

  CMV治療薬マリバビルとバルガンシクロビルの安全性分析

  対象DB：FAERS

  11. The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system.

  ニボルマブのRWDによる安全性シグナル分析

  対象DB：FAERS

  12. Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system.

  チスレリズマブ安全性評価

  対象DB：FAERS

  13. Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database.

  薬剤関連視力ぼやけリスク評価

  対象DB：FAERS

  14. Disproportionality analyses of Tapinarof-related adverse events based on the FAERS database.

  タピナロフ安全性評価

  対象DB：FAERS

  15. Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

  カプマチニブ関連の意外な副作用の特定

  対象DB：FAERS

  16. Pharmacovigilance analysis of secondary primary malignancies and antibiotic interactions in CAR-T cell therapies.

  CAR-T療法と抗生物質の二次がんリスク評価

  対象DB：FAERS

  17. TNF-alpha Inhibitor Associated Psoriasis in Rheumatoid Arthritis and Inflammatory Bowel Disease Patients: A Disproportionality Analysis Using the FDA Adverse Event Reporting System.

  TNF-α阻害剤による乾癬発現の不均衡分析

  対象DB：FAERS

  18. Pharmacovigilance analysis of spondyloarthritis following HPV vaccination based on the VAERS database.

  HPVワクチンと脊椎関節症の関連性を評価

  対象DB：FAERS,VAERS

  19. Comparison between spinal fusion vs. nonoperative treatment for lumbar degenerative pathology: a systematic review and meta-analysis.

  腰椎変性病変治療の融合術と保存的治療の比較

  対象DB：JADER

  20. Costs of Treating Onasemnogene Abeparvovec-Xioi-Induced Liver Injury.

  オナセムノゲン誘発性肝障害の分析とコスト評価

  対象DB：EudraVigilance

  21. Adverse reactions mediated by (99m)Tc-tetrofosmin: literature review and analysis of post-marketing reports.

  (99m)Tc-tetrofosminの副作用プロファイル分析

  対象DB：EudraVigilance

  22. Comparison of Adverse Events in Pregnant Persons Receiving COVID-19 and Influenza Vaccines: A Disproportionality Analysis Using Combined Data from US VAERS and EudraVigilance Spontaneous Report Databases.

  妊娠中のCOVID-19ワクチンの安全性分析

  対象DB：EudraVigilance

  23. Pharmacovigilance processes in low- and middle-income countries: moving from data collection to data analysis and interpretation.

  薬物監視データ分析のLMICでの評価

  対象DB：VigiBase

  24. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature.

  クロザピンと心筋梗塞の関連性研究

  対象DB：VigiBase

  25. The Enhancing Role of Pharmacovigilance to Conventional Antibiotic Resistance Surveillance: Cross-sectional Identification and Analysis of Reports of Antibiotic Resistance in VigiBase.

  抗生物質耐性のグローバルな調査分析

  対象DB：VigiBase

  26. Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.

  セフトリアキソンの用量と肺炎治療効果の研究

  対象DB：DPC

  27. Time series differences in coagulopathy in mechanically ventilated COVID-19 and bacterial pneumonia patients: a nationwide observational study in Japan.

  COVID-19と細菌性肺炎の凝固異常の比較

  対象DB：JMDC

  28. Does the Japanese insurance system increase outpatient psychiatric treatment for children and adolescents? A retrospective study using open data from the national claims database for 2016 to 2022.

  日本の青少年向け精神医療へのアクセス拡大

  対象DB：NDB

  29. Variations in the Use of Faecal Immunochemical Testing (FIT) in Primary Care in England: A Population-Based Cohort of 531,735 FITs from 495,121 Patients Between 2019 and 2023.

  FITテストの地域間使用率の差

  対象DB：CPRD

  30. Data Resource Profile Update: CPRD GOLD.

  CPRD GOLDのデータリソースプロファイル更新

  対象DB：CPRD

  31. Lamotrigine and Cardiac Arrhythmias: A Target Trial Approach.

  抗てんかん薬と心室性不整脈のリスク比較

  対象DB：CPRD

  32. Association between hypoglycaemic drug de-intensification, mortality and hospital admission in older adults with type 2 diabetes: a cohort study emulating a target trial.

  高齢者の糖尿病薬削減のリスク分析

  対象DB：THIN

  33. Multiple or Single Endocrine Abnormalities Associated with Immune Checkpoint Inhibitors.

  免疫チェックポイント阻害剤に関する研究

  対象DB：DeSC

  34. Association of Migraine Comorbidities with Quality of Life, Work Productivity and Daily Activities: Survey and Medical Claims Data in Japan.

  偏頭痛と合併症の影響を分析する研究

  対象DB：DeSC

  35. Association Between Baseline Diabetes Therapy-Related Quality of Life (DTR-QOL) and Subsequent Risk of All-Cause Mortality: A Prospective Cohort Study (Diabetes Distress and Care Registry at Tenri [DDCRT 26]).

  糖尿病治療と生活の質の関連性研究

  対象DB：DeSC

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み